Madrigal Pharmaceuticals, Inc. (MDGL)
Health Care ยท Pharmaceutical Preparations
Madrigal Pharmaceuticals, Inc. (MDGL) is listed on Nasdaq, where its shares have traded since February 6, 2007. SentiSense covers Madrigal Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Bill Sibold is its chief executive officer. The company reports 915 employees, and its corporate website is www.madrigalpharma.com.
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Latest reported results
Madrigal Pharmaceuticals Inc. reported revenue of $431.3 million for Q3 FY2026, up 50.1% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 403 institutions reported holding MDGL, with 23.6 million shares worth $12.6 billion in aggregate. The largest reported holders were Baker Bros. Advisors, Rtw Investments and Janus Henderson (Jupiter Topco). Of the 5 largest reported holders, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter.
More on MDGL
- MDGL sentiment: whether news and social coverage of Madrigal Pharmaceuticals, Inc. leans bullish or bearish, and the stories driving it.
- MDGL ownership: all 403 reporting institutions, plus insider and congressional trades.
- MDGL financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Madrigal Pharmaceuticals, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Madrigal Pharmaceuticals, Inc. do?
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality.
What sector is MDGL in?
SentiSense classifies Madrigal Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does MDGL stock trade?
Madrigal Pharmaceuticals, Inc. (MDGL) is listed on Nasdaq, where its shares have traded since February 6, 2007.
Who is the CEO of Madrigal Pharmaceuticals, Inc.?
Bill Sibold is the chief executive officer of Madrigal Pharmaceuticals, Inc..